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Abstract
Purpose Cancer anorexia-cachexia syndrome (CACS) is
common in advanced cancer patients and associated with
weight loss, fatigue, impaired quality of life (QoL), and poor
prognosis. The goal of this project was to identify the most
responsive items from two QoL measures in the ROMANA 2
(NCT01387282) phase III global study evaluating anamorelin
HCl in the treatment of non-small cell lung cancer (NSCLC)
cachexia: the Functional Assessment of Chronic Illness
Therapy-Fatigue (FACIT-F) and the Functional Assessment
of Anorexia/Cachexia Therapy (FAACT).
Methods In the ROMANA 2 trial, 477 patients with
unresectable stage III or IV NSCLC and cachexia were to be
enrolled and randomized (2:1) to receive anamorelin HCl or
placebo once daily for 12weeks. All 203 patients who reached
the week 12 visit at the time of data analysis were included.
Co-primary endpoints were change from baseline in lean body
mass and handgrip strength. QoL was a secondary outcome
with FACIT-F and FAACT questionnaires administered at
baseline and at weeks 3, 6, 9, and 12.
Results Two 4-item scales (fatigue/activity and appetite/eat-
ing) from the FACIT-F and FAACT questionnaires, respec-
tively, demonstrated good internal consistency reliability, va-
lidity, and responsiveness (also referred to as the Simplified
Evaluation of Fatigue (SEF) and Simplified Evaluation of
Appetite (SEA), respectively). The estimated important dif-
ference for each scale was 1–2 points.
Conclusions These brief scales provide the psychometric
properties necessary to promote future research in NSCLC
patients with CACS. Additional work should examine the
clinical utility of these scales and their impact on treatment
decision-making.
Keywords Measurement . Anorexia . Cachexia . Fatigue .
Quality of life
Introduction
Cancer anorexia-cachexia syndrome (CACS) is a multifacto-
rial condition characterized by an ongoing loss of skeletal
muscle mass that leads to progressive functional impairment
and cannot be fully reversed through conventional nutritional
support [1, 2]. CACS affects a majority of patients with
advanced cancer and is associated with response to therapy,
a reduction in treatment tolerance, duration of survival, and
quality of life [3]. Accordingly, weight loss and decreased
muscle mass are conditions that warrant close monitoring in
patients with solid tumors, including those with lung cancer.
Lung cancer is the leading cause of cancer-related deaths
worldwide with an estimated 1.37 million deaths attributed to
lung cancer in 2008 [4]. In the USA, 50% of newly diagnosed
patients with non-small cell lung cancer (NSCLC) present
with advanced disease and, in spite of significant advances
in treatment, their adjusted 1-year survival ranges from 12 to
27 % [5]. In a prospective study of patients with stages III and
IV NSCLC, 58 % of patients reported weight loss and when
compared to those who did not report weight loss, those
who did had significantly lower response rates, shorter
progression-free survival, and shorter overall survival [6].
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In addition to a direct impact on response and survival,
maintaining adequate nutrition and minimizing weight loss is
a concern for many patients and their families [7]. A number
of benefits in addition to survival might be associated with
halting the progression of CACS, including enhancing phys-
ical ability and improving quality of life [8]. CACS in patients
with NSCLC is an important area of study given the preva-
lence of the disease, the frequency with which it is associated
with weight loss, and the prognostic implications of weight
loss for patients with advanced NSCLC. Unfortunately, brief,
valid, and reliable patient-reported outcomes of cachexia are
lacking.
Anamorelin HCl is an orally active ghrelin receptor agonist
with appetite-enhancing and anabolic activity. Based on the
data available from phase I and phase II clinical trials,
anamorelin HCl produced an increase in total body weight
and lean body mass in patients with advanced cancer, and
specifically in patients with NSCLC, in addition to increasing
muscle strength and improving quality of life outcomes
[9–13]. Anamorelin is currently being evaluated in three phase
III studies in patients with NSCLC cachexia, including
ROMANA 2 (NCT01387282), a randomized, double-blind,
placebo-controlled, multicenter study to evaluate safety and
efficacy [14].
The goal of this project was (1) to identify, blind to treat-
ment assignment, the most responsive items from among self-
report measures administered in the ROMANA 2 phase III
global study, and (2) to evaluate the validity of the selected
subset of questions for the patient population. Identification of
a brief subset of items to assess cachexia in the context of
NSCLC would thus address an important gap in the research
literature and provide a useful assessment tool to facilitate
treatment decision-making and enhance patient-centered care.
Methods
Samples and procedures
Patient recruitment for the ROMANA 2 trial took place in 7
countries at approximately 50 research sites. Written consent
was obtained from all participants, and the study protocol was
approved by each site’s institutional review board. Patients
were eligible to participate in the study if they were/had
≥18 years of age, diagnosed with unresectable stage III or
IV NSCLC, involuntary weight loss of ≥5 % body weight
within 6 months prior to screening or a screening body mass
index (BMI) <20 kg/m2, a body mass index ≤30 kg/m2, an
ECOG performance status ≤2, an estimated life expectancy of
>4 months, adequate hepatic and renal function, and able to
understand and complywith the protocol tests and procedures.
Patients may have been receiving maintenance chemotherapy,
planning to initiate a new chemotherapy and/or radiation
therapy regimen (within ±14 days of randomization), or may
have completed a chemotherapy and/or radiation therapy and/
or have no plan to initiate a new regimen within 12 weeks
from randomization (at least 14 days must elapse from the
completion of the chemotherapy and/or radiation therapy prior
to randomization).
A total of 477 patients were planned to be randomized to
receive either anamorelin HCl or placebo in a 2:1 ratio. Via an
interactive voice response system (IVRS), central randomiza-
tion stratified patients by geographic region (North America
vs. rest of world), by chemotherapy and/or radiation therapy
status (patients who initiated chemotherapy and/or radiation
therapy within ±14 days of randomization or patients who
were only receiving maintenance chemotherapy vs. patients
who had no plan to initiate chemotherapy and/or radiation
therapy within 12 weeks from randomization), and by weight
loss over the prior 6 months (≤10% of body weight vs. >10 %
of body weight).
Study measures
Demographic information obtained included age, gender,
race, ethnicity, and geographic region. Clinical information
obtained included Karnofsky performance status (KPS), body
weight, BMI, lean body mass (as measured by dual energy X-
ray absorptiometry), muscle strength (as measured by hand-
grip strength), and the Hunger Assessment Scale (HAS),
developed specifically for this trial. The HAS was comprised
of two items: “I have felt hungry,” and “My family and friends
are pleased with my appetite.” The HAS was analogous to the
subjective hunger index from the Grand Hunger Scale [15],
and participants responded to the items using a 0–4 Likert
scale. Quality of life outcome measures included the
Functional Assessment of Cancer Therapy-General (FACT-
G) [16], Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) Subscale [17], and the Functional
Assessment of Anorexia/Cachexia Therapy (FAACT) [18].
The FACIT-F and FAACT have been previously used and
validated in clinical research investigations. The instruments
were provided using certified translations (as available) and
completed by patients in their native language. All assess-
ments were administered at baseline and then at weeks 3, 6, 9,
and 12 of the treatment period.
Analytic strategy
This project followed several steps. First, we analyzed the
ROMANA 2 phase III trial data on a blinded basis to identify
the most responsive items using a preliminary database that
included all 203 patients who had reached the week 12 visit at
the time of data analysis. Second, the most responsive items
were reviewed by the research team at Northwestern
University and Helsinn to identify a “best” list of items to
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analyze further. Third, the “best” items were validated and
analyzed to identify the size of a meaningful difference and
provide clinical interpretation.
Compliance We calculated compliance rates for each ques-
tion on the FACIT-F and FAACT as the proportion of patients
who completed the question at each assessment from those
who completed any question in that assessment.
Identification of most responsive items We conducted a series
of analyses to aid in the selection of a brief subset of the most
responsive items. First, change scores were calculated for all
FACIT-F and FAACT items as the week 12 score minus the
baseline score. Then, we formed groups of patients based on
whether their KPS improved, worsened, or stayed the same.
Analysis of variance (ANOVA) was used to compare item
change scores between these groups. A similar set of item
change scores was used to compare patients classified into
similar groups (improved, worsened, or unchanged) as deter-
mined by change in lean body mass, handgrip strength, and
body weight.
Effect sizes to aid in the interpretation of the magnitude of
the change were calculated. Items were flagged as “respon-
sive” if they met the following criteria: (1) the effect size for at
least one of the change groups was >0.30 in magnitude and in
the expected direction, (2) the effect size in the other change
group was in the expected direction, and (3) the effect size for
the unchanged group fell between. Pearson correlation coef-
ficients were calculated between the item change scores and
the changes in KPS, lean body mass, handgrip strength, body
weight, and the Hunger Assessment Scale items. Items were
considered responsive if the correlation coefficient was greater
than 0.25. These criteria were defined based on standard
guidelines for interpreting effect sizes and correlations while
also targeting the identification of a brief number of “most
responsive” items.
Internal consistency reliability Pearson correlation coeffi-
cients were calculated among all pairs of responsive items at
each visit. Cronbach’s coefficient alpha was calculated to
evaluate the internal consistency reliability of that set of items.
We also examined these item-total correlations to identify
items with poor correlations with the total.
Known-groups validity We conducted cross-sectional analy-
ses of scores focused on differentiating definable (“known”)
groups according to appropriate clinical anchor variables.
Groups were formed according to KPS, the questions of the
Hunger Assessment Scale, lean body mass, and handgrip
strength. We used ANOVA to compare mean scores between
these groups. We expected that patients with worse
performance/hunger status would have worse mean summary
scores. Effect sizes (mean difference/pooled standard
deviation) were calculated for group comparisons to provide
an indication of the magnitude of these group differences.
Convergent validity We hypothesized that the questionnaire
summary scores would be associated with fatigue, as mea-
sured by the FACIT-F scale, anorexia/cachexia, as measured
by the FAACT, and general quality of life/functioning, as
measured by the FACT-G. We further anticipated that scores
would be associated with clinical variables and the items of
the Hunger Assessment Scale. The association between the
summary scores and these other measures was evaluated using
Pearson correlations at each assessment. Moderate correla-
tions in the range of 0.3 to 0.7 were expected.
Responsiveness As in the assessment of convergent validity,
we hypothesized that changes in the summary scores would be
moderately associated with changes in the FACIT-F, FACT-G,
FAACT, lean body mass, handgrip strength, body weight, and
Hunger Assessment Scale. To evaluate this, first change scores
were calculated for all instruments by subtracting the baseline
score. Pearson correlation coefficients were then calculated be-
tween the brief scale change scores and the FACIT-F, FACT-G,
FAACT, lean body mass, handgrip strength, body weight, and
Hunger Assessment Scale change scores.
We formed groups of patients based on whether their
performance status improved, worsened, or stayed the same.
ANOVA was used to compare questionnaire change scores
between these groups. A similar comparison of change scores
was used to compare patients between change groups defined
by lean body mass change, handgrip strength change, and
body weight change. Effect sizes were calculated.
Important differences and clinical interpretation Distribution-
and anchor-based methods were used to identify important
differences for the new scale scores. Based upon other work
[19, 20], distribution-based methods include 1/3 standard
deviation (SD), 1/2 SD, and one standard error of measure-
ment (SEM). Anchor-based methods [21] utilized cross-
sectional and longitudinal data.
The randomized treatment arms were collapsed for all
analyses described above and data remained blinded. There
was no imputation of missing data and no adjustment for
multiple comparisons. Analyses were conducted with SAS
v9.3 (SAS Institute, Cary, NC).
Results
Descriptive characteristics of sample
A preliminary database lock was used for this study, selecting
all patients who had reached the 12-week follow-up time
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when the data were pulled (February 2013). A total of 383
enrolled patients were included at the time of data analysis.
Baseline demographic and clinical characteristics of the sam-
ple are presented in Table 1. The mean age was 63.3 years
(SD=8.7, range=33 to 88).
Compliance
The number of patients remaining on study at each assessment
was 325, 274, 233, and 203, for weeks 3, 6, 9, and 12,
respectively. Item level compliance for the FACIT-F and
FAACTwas greater than 95% for all items except for optional
item GS7 (“I am satisfied with my sex life”) which had
compliance levels of 34–41 %.
Confirmation of most responsive items
Table 2 summarizes the results of the group and correlation
analyses. The items were sorted according to the number of
variables to which they were responsive in these two analyses.
The top eight items were selected as the subset of the most
responsive items: ACT1—The amount I eat is sufficient
to meet my needs, ACT9—Family/friends are pressuring
me to eat, ACT10—When I eat I seem to get full
quickly, C6—I have a good appetite, AN12—I am too
tired to eat, GP7—I am forced to spend time in bed,
HI7—I feel fatigued, and HI12—I feel weak all over.
These eight items fell into two distinct categories with
the first four measuring appetite/eating and the last four
measuring fatigue/activity. Therefore, two separate
scores were created by summing the responses to the
four items in each scale. The validity of these two 4-
item scale scores was assessed in the remainder of this
report.
Internal consistency reliability
Fatigue/activity items were highly intercorrelated with inter-
item correlations of 0.45 or greater at each time. Inter-item
correlations among appetite/eating items were generally great-
er than 0.20 with the exception of ACT9 (family/friends
pressuring to eat) with ACT1 (amount eat sufficient to meet
needs). Cronbach’s coefficient alpha for the fatigue/activity
scale was 0.83, 0.84, 0.84, 0.85, and 0.87 at baseline and
weeks 3, 6, 9, and 12, respectively. All item-total correlations
were at least 0.55. Cronbach’s coefficient alpha for the
appetite/eating scale was 0.71, 0.73, 0.71, 0.73, and 0.76 at
baseline and weeks 3, 6, 9, and 12, respectively. All item-total
correlations were greater than 0.35.
Scale scores
The brief 4-item fatigue/activity and appetite/eating scores
(also referred to as the Simplified Evaluation of Appetite
(SEA) and Simplified Evaluation of Fatigue (SEF), re-
spectively) were calculated according to standard FACIT
measurement system guidelines. Specifically, negatively
worded items were reverse scored and then all item
scores were summed to create total scores such that
higher scores indicated better quality of life or lower
symptom levels. Descriptive statistics for these calculat-
ed scores are presented in Table 3.
Known-groups validity
At baseline, fatigue/activity scores differed between KPS
groups with effect sizes for differences between adjacent
groups of 0.34 (p=0.001). A similar relationship was ob-
served at weeks 6 and 12, with slightly larger effect sizes of
0.38 to 0.53 (p<0.001). Although not previously hypothe-
sized, fatigue/activity scores also differed between groups
defined by nondominant handgrip strength and the Hunger
Table 1 Baseline sample characteristics (N=383)
Demographic characteristics N %
Gender
Female 104 27 %
Male 279 73 %
Race/ethnicity
Asian 1 0 %
Black or African American 2 1 %
Hispanic or Latino 1 0 %
Other 2 1 %
White 378 99 %
Country
Poland 176 46 %
Russia 92 24 %
Hungary 75 20 %
Australia 19 5 %
United States of America 11 3 %
Israel 9 2 %
United Kingdom 1 0 %
Clinical characteristics Mean (SD) Range
Karnofsky performance status 79.3 (9.8) 50–100
Body mass index 22.2 (3.7) 14–30
Body weight, kg 63.0 (13.0) 34–98
Nondominant handgrip strength 28.6 (11.4) 5–58
Lean body mass, kg 43.9 (8.1) 24–71
Patient-reported outcome scores Mean (SD) Range
FAACT subscale 27.7 (8.8) 2–48
FACIT-fatigue subscale 27.5 (10.8) 0–52
FACT-G 64.3 (15.9) 7–104
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Table 2 Summary of item responsiveness
Change from baseline to
week 12 in…













ACT10: When I eat I seem to get full quickly O XO O XO X X 8
ACT1: Amount I eat sufficient to meet my needs XO O XO X X 7
ACT9: Family/friends are pressuring me to eat O XO XO O X 7
AN12: I am too tired to eat O O O O X X 6
C6: I have a good appetite XO XO X X 6
GP7: I am forced to spend time in bed XO O O X X 6
HI12: I feel weak all over O O O O X 5
HI7: I feel fatigued O O O O X 5
ACT6: Interest in food drops when I try to eat O O X X 4
AN2: I feel tired O O O X 4
AN4: Trouble finishing things because I’m tired O O O X 4
GF2: My work is fulfilling XO O X 4
GP6: I feel ill O O O X 4
ACT3: Most food tastes unpleasant to me O O X 3
ACT4: I am concerned about how thin I look XO X 3
AN1: I feel listless (‘washed out’) O X X 3
AN3: Trouble starting things because I’m tired O O X 3
AN5: I have energy O O X 3
AN8: I need to sleep during the day XO O 3
GE1: I feel sad O O X 3
O2: I have been vomiting O X X 3
ACT13: My general health is improving X X 2
ACT7: Difficulty eating rich/heavy foods O X 2
AN7: I am able to do my usual activities O X 2
GF1: I am able to work (include work at home) O O 2
GP1: I have a lack of energy O O 2
GP5: I am bothered by side effects of treatment O X 2
ACT2: I am worried about my weight X 1
AN16: I limit my social activity because too tired X 1
GE6: I worry that my condition will get worse O 1
GF3: I am able to enjoy life X 1
GF6: I’m enjoying things I usually do for fun O 1
GP2: I have nausea O 1
GP3: I have trouble meeting needs of my family O 1
GS3: I get support from my friends O 1
GS7: I am satisfied with my sex life X 1
ACT11: I have pain in my stomach area 0
AN14: I need help doing my usual activities 0
AN15: Frustrated by being too tired to do things 0
GE2: Satisfied w/how I’m coping w/my illness 0
GE3: Losing hope in fight against my illness 0
GE4: I feel nervous 0
GE5: I worry about dying 0
GF4: I have accepted my illness 0
GF5: I am sleeping well 0
GF7: Content w/quality of my life right now 0
GP4: I have pain 0
GS1: I feel close to my friends 0
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Assessment Scale item “My family and friends are pleased
with my appetite” at all assessments (p<0.005).
Baseline appetite/eating scores differed significantly be-
tween “I have felt hungry” groups (p<0.001) but effect sizes
for differences between adjacent groups were small to mod-
erate (0.13 to 0.56). For “My family and friends are pleased
with my appetite” groups, the effect sizes for differences
between adjacent group were large (0.66 to 0.84, p<0.001).
Again, similar relationships were observed at weeks 6 and 12,
with slightly larger effect sizes (0.37 to 1.31, p<0.001).
Although not previously hypothesized, appetite/eating scores
also differed between groups defined by nondominant hand-
grip strength and KPS at all assessments (p<0.004).
Convergent validity
Pearson correlation coefficients at each assessment between the
brief scale scores and the existing measures are presented in
Table 4. As hypothesized, the fatigue/activity and appetite/eating
scores were associated with fatigue, as measured by the FACIT-F
scale, anorexia/cachexia, as measured by the FAACT, and general
quality of life/functioning, as measured by the FACT-G. Fatigue/
activity scores were also moderately correlated with responses to
the HAS item “My family and friends are pleased with my
appetite.” Appetite/eating scores were more strongly correlated
with that item and moderately correlated with “I have felt
hungry.” Correlations with KPS and nondominant handgrip
strength were small to moderate for both scales.
Responsiveness
Pearson correlation coefficients between the brief scale
change scores and the FACIT-F, FACT-G, FAACT, lean body
mass, handgrip strength, body weight, and Hunger
Assessment Scale change scores are presented in Table 5. As
hypothesized, changes in fatigue/activity and appetite/eating
scores were associated with changes in fatigue, as measured
by the FACIT-F scale, anorexia/cachexia, as measured by the
FAACT, and general quality of life/functioning, as measured
by the FACT-G. Fatigue/activity change scores were also
moderately correlated with changes in responses to the item
“My family and friends are pleased with my appetite.”
Appetite/eating change scores were more strongly correlated
with changes in that item and moderately correlated with
changes in “I have felt hungry” and body weight.
Correlations with changes in KPS and nondominant handgrip
strength were small for both scales.
Important differences and clinical interpretation
The distribution-based estimates are summarized in Table 6. Of
the cross-sectional anchor-based analyses, many effect sizes for
comparison of KPS and “My family and friends are pleased with
my appetite” groups met the criteria for consideration and are
listed in Table 6. For the longitudinal analyses, however, only the
body weight change group comparisons met the criteria and only
for the appetite/eating score. The estimated (minimally) impor-
tant difference for the fatigue/activity scale was 1.3 to 1.9 points;
for the appetite/eating scale, it was 1.2 to 2.0 points; that is,
roughly 1–2 points for both scales.
Discussion
This study identified eight of the most responsive items from
the FACIT-F and FAACTscales for use in patients undergoing
Table 2 (continued)
Change from baseline to
week 12 in…













GS2: I get emotional support from my family 0
GS4: My family has accepted my illness 0
GS5: Satisfied with family communication about my illness 0
GS6: Close to person who is my main support 0
X responsive in correlation analysis, O responsive in grouped analysis
Table 3 Descriptive statistics for fatigue/activity and appetite/eating
scores
Baseline Week 3 Week 6 Week 9 Week 12
Fatigue/activity
N 378 314 273 227 196
Mean (SD) 9.1 (3.7) 9.4 (3.9) 9.8 (3.8) 10.0 (3.8) 9.7 (3.8)
Range 0–16 0–16 0–16 1–16 1–16
Appetite/eating
N 378 312 273 226 196
Mean (SD) 8.0 (3.8) 9.5 (3.8) 9.7 (3.5) 9.7 (3.6) 9.8 (3.6)
Range 0–16 0–16 1–16 1–16 0–16
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therapy for cancer-related anorexia/cachexia. These eight
items were scored as two scales of four items each:
fatigue/activity and appetite/eating. Scores differed be-
tween groups defined by performance status, nondomi-
nant handgrip strength, lean body mass, and items
assessing self-perceptions of hunger and others’ satisfac-
tion with patient’s appetite. As expected, fatigue/activity
and appetite/eating scores were associated with fatigue,
anorexia/cachexia, and general quality of life.
The fatigue/activity and appetite/eating scales demonstrat-
ed strong psychometric properties. These two scales had good
internal consistency reliability across multiple assessments
and when examining change from baseline. In addition,
changes in fatigue/activity and appetite/eating scores
were not merely limited to associations with changes
in fatigue (FACIT-F) and appetite (Hunger Assessment
Scale), respectively, but were also associated with
changes in anorexia/cachexia, general quality of life,
and body weight with those gaining (or losing) the most
weight reporting small but significant improvements (or
declines) in scores. Similar associations were seen with
change in lean body mass. Collectively, these findings
underscore the potential utility of these brief subscales
for assessing and better understanding cachexia in pa-
tients with advanced NSCLC.
Importantly, the brief versions of the FACIT-F and FAACT
subscales compared quite favorably to their longer counter-
parts. Within this current sample, the correlations between the
fatigue/activity and the FACIT-F and between the appetite/
eating and the FAACTwere strong across all assessments, r=
0.91 to 0.93 and r=0.68 to 0.77 (Table 4). When compared to
the validation samples [18, 22], internal consistency for the
fatigue/activity scale had slightly lower internal consistency
(range 0.83–0.87 vs. 0.93–0.95), but the appetite/eating scale
Table 4 Correlations between brief scale scores and existing measures (convergent validity)
Variable Baseline Week 3 Week 6 Week 9 Week 12
Correlation with fatigue/activity scores
Nondominant handgrip strength 0.26** NA 0.27** NA 0.28**
FAACT 0.68** 0.77** 0.83** 0.76** 0.76**
FACIT-fatigue scale 0.91** 0.92** 0.93** 0.93** 0.91**
FACT-G physical well-being 0.74** 0.83** 0.83** 0.81** 0.78**
FACT-G emotional well-being 0.47** 0.62** 0.65** 0.52** 0.59**
FACT-G social/family well-being 0.04 0.09 0.20** 0.19* 0.10
FACT-G functional well-being 0.41** 0.42** 0.51** 0.50** 0.52**
FACT-G total 0.59** 0.71** 0.77** 0.69** 0.68**
Karnofsky performance status 0.23** 0.22** 0.31** 0.20* 0.37**
Lean body mass 0.19** NA 0.13* NA 0.15*
Body weight 0.18** 0.16* 0.11 0.12 0.16*
I have felt hungry 0.12* 0.06 0.10 0.09 0.19*
My family and friends are pleased with my appetite 0.38** 0.29** 0.33** 0.37** 0.46**
Correlation with appetite/eating scores
Nondominant handgrip strength 0.23** NA 0.23** NA 0.27**
FAACT 0.68** 0.69** 0.74** 0.75** 0.77**
FACIT-Fatigue scale 0.56** 0.49** 0.60** 0.58** 0.66**
FACT-G physical well-being 0.45** 0.49** 0.54** 0.57** 0.64**
FACT-G emotional well-being 0.29** 0.38** 0.44** 0.41** 0.47**
FACT-G social/family well-being 0.09 0.07 0.12 0.18* 0.07
FACT-G functional well-being 0.45** 0.44** 0.44** 0.46** 0.53**
FACT-G total 0.46** 0.49** 0.54** 0.55** 0.59**
Karnofsky performance status 0.20** 0.26** 0.31** 0.30** 0.27**
Lean body mass 0.18** NA 0.17* NA 0.19*
Body weight 0.25** 0.22** 0.21** 0.32** 0.19*
I have felt hungry 0.27** 0.37** 0.29** 0.27** 0.35**
My family and friends are pleased with my appetite 0.70** 0.68** 0.65** 0.67** 0.71**
NA not applicable as handgrip strength and lean body mass were only assessed at baseline, week 6 and week 12
*p<0.05; **p<0.001
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was equivalent (range 0.71–0.76 vs. 0.76). For known-groups
validity, the fatigue/activity scale had a significant rela-
tionship to performance status scores in the validation
sample as well as this current sample (both p<0.05).
The responsiveness of the appetite/eating scale was also
quite similar when examining the relationship to perfor-
mance status in the validation sample compared to the
current sample (both p<0.05).
This study has some limitations. First, the predominantly
white, non-Hispanic, male sample may limit the generalizabil-
ity of the findings. Second, although this study intentionally
focused on patients with advanced NSCLC only, cachexia is a
significant concern among patients with other types of cancer
as well. These brief scales should be tested in other relevant
clinical populations. Third, in the process of validating the
brief scales, some of our outcomes included redundant item
content. We retained overlapping items and reported the find-
ings because they provided the most accurate portrayal of
association between original and revised (abbreviated)
scales. This was important when evaluating the construct
validity of our new measures with well-established and/or
face-valid measures.
In summary, this multi-site, longitudinal study included
a wide range of important clinical and patient-reported
outcomes to identify and validate a brief measure of
CACS in patients with advanced stage NSCLC. The re-
sults indicated that the fatigue/activity and appetite/eating
scales derived from the FACIT-F and FAACT were reli-
able, valid, and responsive measures. The estimated im-
portant difference for each scale was approximately 1 to 2
points, suggesting guidelines for evaluation of clinically
significant levels of change and highlighting the utility
Table 5 Correlations between brief scale change scores and existing measures’ change scores (responsiveness)
Change from baseline in… Week 3 Week 6 Week 9 Week 12
Correlation with fatigue/activity change scores
Nondominant handgrip strength NA 0.19* NA 0.08
FAACT 0.60** 0.62** 0.66** 0.71**
FACIT-fatigue scale 0.84** 0.84** 0.82** 0.86**
FACT-G physical well-being 0.68** 0.70** 0.67** 0.69**
FACT-G emotional well-being 0.47** 0.41** 0.37** 0.46**
FACT-G social/family well-being −0.05 −0.17* 0.12 0.11
FACT-G functional well-being 0.30** 0.30** 0.36** 0.40**
FACT-G total 0.55** 0.52** 0.58** 0.64**
Karnofsky performance status 0.13* 0.17* 0.20* 0.23*
Lean body mass NA 0.18* NA 0.18*
Body weight 0.19** 0.22** 0.18* 0.28**
I have felt hungry 0.11 0.15* 0.23** 0.28**
My family and friends are pleased with my appetite 0.29** 0.28** 0.39** 0.43**
Correlation with appetite/eating change scores
Nondominant handgrip strength NA 0.11 NA 0.13
FAACT 0.62** 0.69** 0.70** 0.75**
FACIT-fatigue scale 0.38** 0.44** 0.40** 0.50**
FACT-G physical well-being 0.37** 0.43** 0.49** 0.56**
FACT-G emotional well-being 0.29** 0.25** 0.19* 0.33**
FACT-G social/family well-being −0.03 −0.06 0.18* 0.11
FACT-G functional well-being 0.21** 0.24** 0.27** 0.30**
FACT-G total 0.32** 0.36** 0.44** 0.50**
Karnofsky performance status 0.18* 0.14* 0.25** 0.18*
Lean body mass NA 0.27** NA 0.25**
Body weight 0.30** 0.37** 0.36** 0.40**
I have felt hungry 0.27** 0.35** 0.31** 0.38**
My family and friends are pleased with my appetite 0.54** 0.56** 0.56** 0.65**
NA not applicable as handgrip strength and lean body mass were only assessed at baseline, week 6 and week 12
*p<0.05; **p<0.001
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of these assessment tools in clinical trials. As mentioned
above, future work should examine the generalizability of
these findings to patients with other solid tumors who are
prone to CACS. In addition, clinicians and researchers
alike may benefit from implementing this tool in clinical
practice settings to examine ways in which it may facili-
tate treatment decision-making, improve patient-centered
care, and enhance quality of life outcomes for patients
suffering from cancer-related cachexia.
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Table 6 Distribution-based and anchor-based estimates of important differences
Fatigue/activity Appetite/eating
1/3 SD Baseline 1.2 1.3
Week 3 1.3 1.3
Week 6 1.3 1.2
Week 9 1.3 1.2
Week 12 1.3 1.2
1/2 SD Baseline 1.8 1.9
Week 3 2.0 1.9
Week 6 1.9 1.8
Week 9 1.9 1.8
Week 12 1.9 1.8
SEM Baseline 1.5 2.0
Week 3 1.6 2.0
Week 6 1.5 1.9
Week 9 1.5 1.8
Week 12 1.4 1.8
Cross-sectional anchors Baseline–My friends and family are pleased
with my appetite
Not at all vs a little bit 1.42 A little bit vs somewhat 2.15
A little bit vs somewhat 1.35 Somewhat vs quite a bit 1.97
Somewhat vs quite a bit 1.20 Quite a bit vs very much 2.22
Week 6–Performance status <70 vs 70–80 1.61 <70 vs 70–80 1.42
70–80 vs 90–100 1.42 70–80 vs 90–100 1.55
Week 6–My friends and family are pleased
with my appetite
A little bit vs somewhat 1.85 Not at all vs a little bit 1.16
Somewhat vs quite a bit 1.73 Quite a bit vs very much 1.06
Week 12–Performance status <70 vs 70–80 1.88
70–80 vs 90–100 1.92
Week 12–I have felt hungry A little bit vs somewhat 1.94
Somewhat vs quite a bit 0.85
Week 12–My friends and family are pleased
with my appetite
Not at all vs a little bit 1.24 Not at all vs a little bit 2.13
A little bit vs somewhat 2.43 Somewhat vs quite a bit 1.14
Somewhat vs quite a bit 0.81
Quite a bit vs very much 1.48
Longitudinal anchors Week 6–Change in body weight Decreased 3 kg or more 0.69
Increased 1–2.99 kg 1.47
Week 9–Change in body weight Decreased 3 kg or more 2.33
Increased 1–2.99 kg 1.35
Week 12–Change in body weight Decreased 3 kg or more 2.27
Increased 1–2.99 kg 1.21
Median (IQR) 1.5 (1.3–1.9) 1.8 (1.2–2.0)
For anchor-based analyses, only group comparisons that met all three criteria are presented: (1) correlation ≥0.3, (2) group n≥10, and (3) effect size
between 0.2 and 0.8
IQR interquartile range
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